MYMD PHARMACEUTICALS INC (MYMD)
US62856X2018 - Common Stock
Tuesday's session: gap up and gap down stocks
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
Vivos Therapeutics stock is up on Tuesday as VVOS investors react to the company securing full Medicare reimbursement for its OSA device.
Why Is Vincerx Pharma (VINC) Stock Down 64% Today?
Vincerx Pharma stock is falling hard on Tuesday after the company failed to impress VINC shareholders with its latest clinical trial update.
Tuesday's pre-market session: top gainers and losers
Get insights into the top gainers and losers of Tuesday's pre-market session.
Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?
MyMD Pharmaceuticals stock is rising on Tuesday as MYMD investors react to new amendment to a securities purchase agreement.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday as we check out all of the biggest stories moving shares this morning!
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
MyMD Pharmaceuticals down after announcing reverse stock split (NASDAQ:MYMD)
MyMD Pharmaceuticals announces a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares to maintain its...
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
Top Buys by Top Brass: Chief Legal Officer Rivard's $166.5K Bet on MYMD
